S-(4-methoxybenzyl)isothiourea | 46234-22-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: S-(4-methoxybenzyl)isothiourea
• 英文别名: 2-(4-methoxybenzyl)isothiourea；4-methoxybenzylisothiourea；(4-Methoxy-benzyl)-isothioharnstoff；p-Methoxy-benzyl-thiuronium；(4-methoxyphenyl)methyl carbamimidothioate
• CAS: 46234-22-4
• 化学式: C₉H₁₂N₂OS
• mdl: MFCD00995661
• 分子量: 196.273
• InChiKey: UZINFBQPZVMBMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  84.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  苯那地平杂质9 、 S-(4-methoxybenzyl)isothiourea 生成 1,4-dihydro-2-<<(4-methoxyphenyl)methyl>thio>-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid methyl ester
  参考文献：
  名称：

  ATWAL, KARNAIL

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲氧基氯苄 在 硫脲 作用下， 以 四氢呋喃 为溶剂， 生成 S-(4-methoxybenzyl)isothiourea
  参考文献：
  名称：

  Substituted 1,4-dihydropyrimidine-5-carboxylate compounds, their

  摘要：

  提供了式（I）的新化合物，包括它们的3,4-二氢嘧啶互变体形式，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、X和n如规范中定义，并且它们的光学异构体和消旋体以及药学上可接受的盐；以及它们的制备方法、含有它们的组合物以及它们在治疗中的用途。这些化合物是N型神经元钙通道拮抗剂，可用于治疗脑血管缺血和疼痛。

  公开号：

  US06057332A1

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2004111013A1

  公开（公告）日：2004-12-23

  The present invention relates to new compounds useful for the treatment or prevention of hepatitis C, process for preparing them, and a composition for the treatment or prevention of hepatitis C comprising the compounds as an active ingredient.

  本发明涉及用于治疗或预防丙型肝炎的新化合物，制备这些化合物的方法，以及包含这些化合物作为活性成分的用于治疗或预防丙型肝炎的组合物。
• Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors
  申请人：Malherbe Pari

  公开号：US20050197337A1

  公开（公告）日：2005-09-08

  The present invention relates to compounds of formula whereinX is —S— or —NH—; R 3 /R 4 together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR 2 , —CONR 2 , —CO-lower alkyl or benzyl; or R 3 /R 4 form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; and R, R 1 , R 2 , and R 5 are as defined herein and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds of the invention are active on the GABA B receptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.

  本发明涉及具有以下公式的化合物：其中X是-S-或-NH-；R3/R4与它们所连接的N原子一起形成一个非芳香性的5、6或7元环，该环除了N原子外，还可以选择性地包含一个额外的杂原子，该杂原子选自O、S和N的组中，并且环可以选择性地被羟基、低级烷基、低级烷氧基、-NR2、-CONR2、-CO-低级烷基或苄基取代；或者R3/R4与它们所连接的N原子一起形成一个含有两个或三个环的杂环体系，该体系可以选择性地包含一个或两个额外的杂原子，这些杂原子选自N和O的组中，并且含有的碳原子数不超过20个；以及R、R1、R2和R5如本文所述，以及药用适当的酸加成盐。已经发现，本发明的化合物对GABAB受体具有活性，因此可用于治疗焦虑、抑郁、癫痫、精神分裂症、认知障碍、痉挛和骨骼肌僵直、脊髓损伤、多发性硬化症、肌萎缩侧索硬化症、脑瘫、神经性疼痛以及与可卡因和尼古丁相关的渴望、精神疾病、恐慌症、创伤后应激障碍和胃肠功能障碍。
• [EN] 4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY<br/>[FR] DERIVES DE 4-(SULFANYL-PYRIMIDINE-4-YLMETHYLE)-MORPHOLINE ET COMPOSES ASSOCIES UTILISES EN TANT QUE LIGANDS RECEPTEURS GABA DANS LE TRAITEMENT DE L'ANXIETE, DE LA DEPRESSION ET DE L'EPILEPSIE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005094828A1

  公开（公告）日：2005-10-13

  The present invention relates to compounds of Formula (I) wherein X is -S- or -NH-; R1 is alkyl, alkenyl, arylalkyl, arylalkenyl or aryl-O-alkyl, wherein the aryl groups are optionally substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or lower halogen-alkyl; R2 is hydrogen, lower alkyl or cycloalkyl; R3/R4 may form together with the N-atom to which they are attached a non aromatic5, 6 or 7 membered ring, which may contain in addition to the N-atom one additional heteroatom selected from the group consisting of O, S or N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, -NR2, -CONR2, -CO-lower alkyl or benzyl; or may form together with the N-atom to which they are attached a heterocyclic ring system, containing at least two rings and which may contain one or two additional heretoatoms, selected from the group consisting of N or O; R is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds are active on the GABAB receptor and therefore useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders or gastro-intestinal disorders.

  本发明涉及公式(I)所示的化合物，其中X是-S-或-NH-；R1是烷基、烯基、芳烷基、芳烯基或芳基-O-烷基，其中芳基可被选自低烷基、低烷氧基、卤素或低卤代烷基的一个或多个取代基所取代；R2是氢、低烷基或环烷基；R3/R4可与它们所连接的N原子共同形成一个非芳香性的5、6或7元环，该环除了N原子外，还可包含一个选自O、S或N的附加杂原子，并且该环可被羟基、低烷基、低烷氧基、-NR2、-CONR2、-CO-低烷基或苄基所取代；或者可与它们所连接的N原子共同形成一个含有至少两个环的杂环体系，该体系可包含一个或两个选自N或O的附加杂原子；R是氢或低烷基；R5是氢或低烷基；以及涉及药用适宜的酸加成盐。已经发现，这些化合物对GABAB受体具有活性，因此可用于治疗焦虑、抑郁、癫痫、精神分裂症、认知障碍、痉挛和骨骼肌僵直、脊髓损伤、多发性硬化症、肌萎缩性侧索硬化症、脑瘫、神经性疼痛以及与可卡因和尼古丁相关的渴望、精神疾病、恐慌症、创伤后应激障碍或胃肠功能紊乱。
• Structure-Activity Relationship Study of the Bacterial Actin-Like Protein MreB Inhibitors: Effects of Substitution of Benzyl Group in<i>S</i>-Benzylisothiourea
  作者：Noritaka IWAI、Takuya FUJII、Hirokatsu NAGURA、Masaaki WACHI、Tomoya KITAZUME

  DOI：10.1271/bbb.60443

  日期：2007.1.23

  We comprehensively investigated the effects of substitution of the benzyl group in S-benzylisothiourea derivatives on antibacterial activity, because we found previously that some substitutions enhanced it. A 2,4-Cl2-derivative was found to be the most effective compound, it was stronger than the original one in Gram-negative rod shaped-bacteria such as Escherichia coli and Salmonella typhimurium.

  我们全面研究了S-苄基异硫脲衍生物中苄基取代基对抗菌活性的影响，因为我们此前发现某些取代基能增强这一活性。我们发现2,4-二氯衍生物是最有效的化合物，它在革兰氏阴性杆菌如大肠杆菌和鼠伤寒沙门氏菌中的抗菌活性强于原化合物。
• DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
  申请人：——

  公开号：US20040038855A1

  公开（公告）日：2004-02-26

  This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence.

  该发明提供了编码人类MCH1受体的孤立核酸，纯化的人类MCH1受体，含有编码人类MCH1受体的孤立核酸的载体，含有这种载体的细胞，针对人类MCH1受体的抗体，用于检测编码人类MCH1受体的核酸探针，与编码人类MCH1受体的核酸的独特序列互补的反义寡核苷酸，表达编码正常或突变人类MCH1受体的转基因非人类动物，分离人类MCH1受体的方法，治疗与人类MCH1受体活性相关的异常的方法，以及确定化合物与哺乳动物MCH1受体结合的方法。该发明还提供了一种治疗患有尿失禁的受试者的方法，包括向受试者投予足以治疗受试者尿失禁的MCH1拮抗剂。